


## Global Orthopedic Biomaterials Market Fueled by Incidence Rate of Musculoskeletal and Neurodegenerative Diseases

VANCOUVER, BRITISH COLUMBIA, CANADA, January 9, 2023
/EINPresswire.com/ -- iData Research, a global consulting and market research firm, has just released new research on the Global Orthopedic Biomaterials market across 70 countries and 5 continents, addressing key insights and the consequences of COVID-19 in 2021, 2022, and beyond. As with the majority of orthopedic therapies, the elderly demographic is a major market driver. Along with the increasing size of this demographic, the incidence of



osteoarthritis (OA) and other forms of degenerative disease are also expected to grow, driving the demand for orthopedic biomaterial products.

According to iData's Global Market Report Suite for Orthopedic Biomaterials, the market was



The total market for orthopedic biomaterials (OB) experienced an increase over the previous year, mainly due to the increased prevalence of musculoskeletal and neurodegenerative disease."

Dr. Kamran Zamanian, Senior Partner and CEO

valued at \$5.6 billion in 2022. This is expected to increase over the forecast period to reach approximately \$7.1 billion. This report includes procedure numbers, industry dynamics, unit sales, average selling prices (ASPs), market drivers and limiters, market share statistics, key industry competitors, and more, for the market segments covered.

iData's analysis includes detailed segmentation on the following markets including bone graft substitutes, growth factors, cell therapy, hyaluronic acid viscosupplementation and cartilage repair (appendix only).

Among the many competitors in the global orthopedic biomaterials market, Medtronic, DePuy

Synthes, and Stryker are the top three market share leaders. Medtronic has maintained a strong presence in the total orthopedic biomaterials device market through brand recognition, strong customer support, and a large sales force.

Key Questions Answered in this Report:

How has the Global Orthopedic Biomaterials market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the Global Orthopedic Biomaterials market and how recovery is taking shape?

What are the key regional markets?

What are the key driving factors and challenges in the industry?

What is the structure of the Global Orthopedic Biomaterials market and what are the market shares of key players?

What is the degree of competition in the industry?

To accurately estimate market shares, units sold, average selling prices, product segments, and brands as well as procedural volumes, iData Research uses its proprietary market and procedure databases, as well as hospital purchase order data to complement its primary and secondary research initiatives.

Follow the link below to request a pre-publication summary of our Global Orthopedic Biomaterials market:

https://idataresearch.com/product/orthopedic-biomaterials-market-size-share-and-covid-19-impact-analysis-global-medsuite/

For Further Information

More insights like this can be found in the latest reports by iData. Please email us at info@idataresearch.net or register online for a brochure and synopsis.

About iData

iData Research is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, and pharmaceutical industries.

## www.idataresearch.com

Emma Matrick iData Research +1 604-266-6933 email us here Visit us on social media: Facebook

Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/609729632

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.